Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.

Maxim lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $5 and keeps a Buy rating on the shares. Sana ...

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three-year highs in response to breakthrough innovations and ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

In type 2 diabetes, the body's ability to release insulin is impaired, which leads to high blood glucose levels. Research led ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Sana Biotechnology (SANA) and eBay (EBAY) are two of the stocks rallying this morning despite the market’s losses. Sana is ...

Life without a pancreas involves treatments to replace organ function. Learn how different surgical techniques affect overall ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...